<!DOCTYPE html>

<html lang="en">
<head>
<meta charset="utf-8"/>
<title>article160</title>
<style>
        body {
            font-family: Arial, sans-serif;
            margin: 0;
            padding: 0;
            background-color: #f3f3f3;
        }
        .container {
            max-width: 800px;
            margin: auto;
            background: #fff;
            padding: 20px;
            box-shadow: 0 0 10px rgba(0, 0, 0, 0.1);
        }
        h1, h2 {
            color: #333;
        }
        p {
            line-height: 1.6;
        }
        a {
            text-decoration: none;
            color: #5a5a5a;
        }
        a:hover {
            color: #000;
        }
    </style>
</head>
<body>
<div class="container"><p><a href="../index_gpt.html">Back to Index</a></p><li><a href="https://www.wikijournalclub.org/wiki/MUSTT" style="display:block; margin-bottom:10px;">MUSTT Original</a></li>
<h2><strong>MUSTT</strong></h2>
<div class="container">
<h2><strong></strong></h2>
<div class="container">
<div class="container">
<h2><strong></strong></h2>
<h2><strong></strong></h2>

    "Electrophysiologically Guided Antiarrhythmic Therapy in Coronary Artery Disease Patients". The New England Journal of Medicine. <br/>
<br/>
<h2><strong>Contents</strong></h2><br/>
1 Clinical Question<br/>
2 Bottom Line<br/>
3 Major Points<br/>
4 Guidelines<br/>
5 Design<br/>
6 Population<br/>
6.1 Inclusion Criteria<br/>
6.2 Exclusion Criteria<br/>
6.3 Baseline Characteristics<br/>
7 Interventions<br/>
8 Outcomes<br/>
8.1 Primary Outcome<br/>
8.2 Secondary Outcomes<br/>
9 Funding<br/>
10 Further Reading<br/>
<br/>
<h2><strong>Clinical Question</strong></h2><br/>
Does electrophysiologically guided antiarrhythmic therapy reduce the risk of sudden death among patients with coronary artery disease, a left ventricular ejection fraction of 40 percent or less, and asymptomatic unsustained ventricular tachycardia?<br/>
<br/>
<h2><strong>Bottom Line</strong></h2><br/>
Electrophysiologically guided antiarrhythmic therapy with implantable defibrillators, but not with antiarrhythmic drugs, reduces the risk of sudden death in high-risk patients with coronary disease.<br/>
<br/>
<h2><strong>Major Points</strong></h2><br/>
Patients with coronary artery disease, left ventricular dysfunction, and spontaneous unsustained ventricular tachycardia have a significant risk of sudden death. This study aimed to evaluate if an electrophysiologically guided therapy approach could reduce this risk.<br/>
<br/>
<h2><strong>Guidelines</strong></h2><br/>
Research findings suggested implanting defibrillators (but not the use of antiarrhythmic-drug therapy based on electrophysiologic testing) in patients like those within the trial criteria to provide beneficial outcomes. <br/>
<br/>
<h2><strong>Design</strong></h2><br/>
Randomized, controlled trial with an enrollment period from 1990 to 1996.<br/>
<br/>
<h2><strong>Population</strong></h2><br/>
A total of 704 patients with coronary artery disease, left ventricular ejection fraction of ≤40%, and spontaneous unsustained ventricular tachycardia.<br/>
<br/>
Inclusion Criteria<br/>
Patients with coronary artery disease, a left ventricular ejection fraction ≤40%, asymptomatic unsustained ventricular tachycardia, and sustained tachyarrhythmia induced by programmed stimulation.<br/>
<br/>
Exclusion Criteria<br/>
History of syncope or sustained ventricular tachycardia or fibrillation occurring more than 48 hours after myocardial infarction.<br/>
<br/>
Baseline Characteristics<br/>
Similar across both treatment and placebo groups. Patients had a median ejection fraction of around 29-30%.<br/>
<br/>
<h2><strong>Interventions</strong></h2><br/>
Patients were randomized to receive electrophysiologically guided antiarrhythmic therapy or no therapy. Antiarrhythmic therapy included drugs and/or implantable defibrillators as indicated by electrophysiologic testing.<br/>
<br/>
<h2><strong>Outcomes</strong></h2><br/>
Primary Outcome<br/>
Cardiac arrest or death from arrhythmia.<br/>
<br/>
Secondary Outcomes<br/>
Overall mortality, death from cardiac causes, and the incidence of spontaneous, sustained ventricular tachycardia.<br/>
<br/>
<h2><strong>Funding</strong></h2><br/>
National Heart, Lung, and Blood Institute and multiple pharmaceutical and medical device companies.<br/>
<br/>
<h2><strong>Further Reading</strong></h2><br/>
The full text of this study provides detailed insights into the methodology, results, and implications of the study findings. <br/>
<br/>
Appendix: List of participating investigators and institutions included in the study.
    <p></p>
</div>
</div>
</div>
</div>
</body>
</html>
